Trilitas (tazarotene) NDC 87143-200

NDC codes

FDA NDC Directory

Product NDC (as listed)87143-200Labeler and product segments. Claims need a package NDC.

Product NDC at billing width87143-0200Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
87143-200-30	87143020030	1 TUBE in 1 CARTON (87143-200-30) / 30 g in 1 TUBEMarketed from Jun 15, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Trilitas
Generic name (nonproprietary): tazarotene
Active ingredients: Tazarotene — 1 mg/g
Dosage form: Gel
Route: Topical
Labeler: Perfero Pharma, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 214136
Marketing start: Jun 15, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Retinoids (Chemical structure)
Identifiers: Product ID 87143-200_1f8c91db-194d-430b-a3b7-1d2e94c7b455SPL ID 1f8c91db-194d-430b-a3b7-1d2e94c7b455SPL set ID 1cf1faef-73b8-4ab2-a4c8-521f0bd3fc10RxCUI 313201, 2745155UNII 81BDR9Y8PS
Pharmacologic class: Retinoid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N487143020030 followed by a unit qualifier and the quantity

Package 87143-0200-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 18, 2026.

Indications (excerpt from the label)

Trilitas™ gel, 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement. ( 1.1 ) Trilitas™ gel, 0.1% is indicated for the topical treatment of mild to moderate facial acne vulgaris. ( 1.2 ) Limitations of Use The safety of Trilitas™ gel use on more than 20% body surface area has not been established. ( 1.3 ) 1.1 Plaque Psoriasis Trilitas™ (tazarotene) gel, 0.1% is indicated for the topical treatment of patients with plaque psoriasis of up to 20% body surface area involvement. 1.2 Acne Vulgaris Trilitas™ (tazarotene) gel, 0.1% is also indicated for the topical treatment of patients with facial acne vulgaris of mild to moderate sever…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 214136

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 214136
Product	Strength	Form · route	Labeler	Product NDC
Tazarotene	Tazarotene 1 mg/g	GelTopical	Cosette Pharmaceuticals, Inc.	0713-0804